Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

Second Biologic Might Improve Tolerability of Multi-Food Allergy Immunotherapy



(MedPage Today) — PHILADELPHIA — For multi-allergen oral immunotherapy (mOIT) patients, adding dupilumab (Dupixent) after omalizumab (Xolair) showed promise for cutting the gastrointestinal adverse events (AE) of ongoing mOIT, although perhaps…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments